A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGM-HF
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Mar 2017 According to a Novartis media release, results of post hoc subgroup analysis of patients with reduced ejection fraction heart failure (HFrEF) and diabetes have been published in The Lancet Diabetes & Endocrinology.
    • 18 Mar 2017 According to a Novartis media release, results of post hoc subgroup analysis of patients with reduced ejection fraction heart failure (HFrEF) and diabetes have been presented at the American College of Cardiology (ACC) 66th Annual Scientific Session.
    • 18 Mar 2017 Results of post hoc subgroup analysis of patients with reduced ejection fraction heart failure (HFrEF) and diabetes published in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top